Abstracts - PAGE Meeting (Population Approach Group Europe)

Abstracts (105)

IV-001Xiaoying Chen

DOSE SELECTION BY A MODEL-INFORMED DRUG DEVELOPMENT (MIDD) APPROACH FOR NAPORAFENIB AND TRAMETINIB COMBINATION IN PATIENTS WITH MELANOMA

Thu, Jun 4, 2026 1:40PM–3:10PM

IV-002Jesika Habip Gatenyo

A PK/PD WORKFLOW TO SUPPORT THE SELECTION OF EMPIRICAL ANTIBIOTIC COMBINATIONS: APPLICATION TO NEONATAL SEPSIS IN LOW- AND MIDDLE-INCOME COUNTRIES

Thu, Jun 4, 2026 1:40PM–3:10PM

IV-003Han Liu

Sex differences in sunitinib tolerability and patient-reported outcomes in metastatic renal cell carcinoma: the role of exposure and implications for precision dosing

Thu, Jun 4, 2026 1:40PM–3:10PM

IV-004Van Dong Nguyen

Assessing Vancomycin PK Model Performance Across Trough- and AUC-Based Targets in Diverse Patient Populations

Thu, Jun 4, 2026 1:40PM–3:10PM

IV-005Razan Sakran

Development and Evaluation of an Optimized Busulfan Dosing Strategy in Hematopoietic Stem Cell Transplantation

Thu, Jun 4, 2026 1:40PM–3:10PM

IV-006Johannes Starp

DOES THEORETICAL TARGET ATTAINMENT REFLECT REAL-WORLD TARGET ACHIEVEMENT? AN EVALUATION IN INTENSIVE CARE UNIT PATIENTS RECEIVING PIPERACILLIN AS CONTINUOUS INFUSION

Thu, Jun 4, 2026 1:40PM–3:10PM

IV-007THI THANH TRAN

Physiologically Based Pharmacokinetic Modeling of Rilpivirine to Support Trimester-Specific Dose Optimization in Pregnant Women Living With HIV

Thu, Jun 4, 2026 1:40PM–3:10PM

IV-008Orwa Albitar

PopPK and PKPD Modeling of Oral NLRP3 Inhibitor Supporting Dose Simulation in Parkinson’s Disease

Thu, Jun 4, 2026 1:40PM–3:10PM

IV-009Alex De Nardi

A MINIMAL MECHANISTIC QSP-READY MODEL TO BRIDGE AGGREPHAGY AND MTOR SIGNALING IN ALS

Thu, Jun 4, 2026 1:40PM–3:10PM

IV-010Petra Jauslin

POPULATION PHARMACOKINETIC ANALYSIS OF ORAL, INTRAMUSCULAR IMMEDIATE RELEASE AND SUBCUTANEOUS LONG-ACTING INJECTABLE OLANZAPINE

Thu, Jun 4, 2026 1:40PM–3:10PM

IV-011Camille Vong

A quantitative systems pharmacology (QSP) model of neuroinflammation in Mild Cognitive Impairment and early Alzheimer’s Disease dementia

Thu, Jun 4, 2026 1:40PM–3:10PM

IV-012Guiva Annane

ASSESSMENT OF PIPERACILLIN–TAZOBACTAM VARIABILITY IN OBESITY THROUGH POPULATION PHARMACOKINETIC MODELING

Thu, Jun 4, 2026 1:40PM–3:10PM

IV-013Daniele Boaretti

A lesion-centric extension of a minimal PBPK model to predict anti-tuberculosis drug target attainment in rabbits

Thu, Jun 4, 2026 1:40PM–3:10PM

IV-014Vasileios Chronopoulos

A Translational Multiscale Model Integrating Immune Response, Bacterial Dynamics, and Lung PBPK to Predict Tuberculosis Treatment Response

Thu, Jun 4, 2026 1:40PM–3:10PM

IV-015Sylvain Goutelle

A pharmacometric model of the in vitro co-dynamics of Staphylococcus aureus and three phage candidates

Thu, Jun 4, 2026 1:40PM–3:10PM

IV-016Allan Kengo

Drug interaction between pyrazinamide and standard- and high-dose rifampicin

Thu, Jun 4, 2026 1:40PM–3:10PM

IV-017Chenyao Liu

Population pharmacokinetics–driven optimization of CFU-reduction study design for boosted ethionamide combinations in mice

Thu, Jun 4, 2026 1:40PM–3:10PM

IV-018Ruvarashe Joylyne Madzime

Linezolid Pharmacokinetics in Adults with Rifampicin-Resistant TB: Impact of Pregnancy and Lactation

Thu, Jun 4, 2026 1:40PM–3:10PM

IV-019Laura Mulas

Quantifying host and vaccination determinants of viral dynamics in respiratory infections using community-based PCR data

Thu, Jun 4, 2026 1:40PM–3:10PM

IV-020Italo Poggesi

Population Pharmacokinetic Model of Tebipenem (TBP) in Blood and Plasma after Oral Administration of Tebipenem Pivoxil (TBP-PI) in Adult Participants.

Thu, Jun 4, 2026 1:40PM–3:10PM

IV-021Nichada Seriniyom

PHARMACOKINETICS OF HPMZ TREATMENT IN CYNOMOLGUS MACAQUES: RECOMMENDATIONS FOR A PROSPECTIVE EFFICACY STUDY WITH ANTITUBERCULAR DRUGS.

Thu, Jun 4, 2026 1:40PM–3:10PM

IV-022Bart van Lieshout

THE TRANSLATIONAL ZEBRAFISH LARVAE FRAMEWORK ACCURATELY PREDICTS BEDAQUILINE’S CLINICAL EARLY BACTERICIDAL ACTIVITY AGAINST TUBERCULOSIS

Thu, Jun 4, 2026 1:40PM–3:10PM

IV-023Haini Wen

MODEL-INFORMED DOSING STRATEGIES FOR INHALED AMINOGLYCOSIDES IN NOSOCOMIAL PNEUMONIA

Thu, Jun 4, 2026 1:40PM–3:10PM

IV-024Ludovica Aiello

Development of a mathematical model for the quantitative comparison of RC106 and TMZ efficacy in U87 spheroids

Thu, Jun 4, 2026 1:40PM–3:10PM

IV-025Alieke Bos

A REPEATED TIME-TO-EVENT ANALYSIS OF LENVATINIB-INDUCED DOSE-LIMITING TOXICITIES IN PATIENTS WITH DIFFERENTIATED THYROID CARCINOMA AND METASTATIC RENAL CELL CARCINOMA

Thu, Jun 4, 2026 1:40PM–3:10PM

IV-026Marc Cerou

Model-based assessment of isatuximab monthly dosing regimen in relapsed/refractory multiple myeloma patients using IKEMA phase 3 data

Thu, Jun 4, 2026 1:40PM–3:10PM

IV-027Birses Debir

MECHANISTIC MODELLING OF CRS IN T CELL ENGAGERS – AN APPLICATION FOR BLINATUMOMAB

Thu, Jun 4, 2026 1:40PM–3:10PM

IV-028Tomoko Freshwater

MODEL-INFORMED DOSAGE SELECTION FOR GOCATAMIG, A TRI-SPECIFIC, HALF-LIFE–EXTENDED DLL3-DIRECTED T-CELL ENGAGER IN PATIENTS WITH SMALL CELL LUNG CANCER AND OTHER NEUROENDOCRINE CANCERS

Thu, Jun 4, 2026 1:40PM–3:10PM

IV-029Juan Antonio Garzón Lamarque

INTEGRATED POPULATION SEMI-MECHANISTIC PK/PD MODELING OF HIGH-DOSE METHOTREXATE AND 6-MERCAPTOPURINE EFFECTS ON NEUTROPHIL DYNAMICS IN PEDIATRIC ACUTE LYMPHOBLASTIC LEUKEMIA

Thu, Jun 4, 2026 1:40PM–3:10PM

IV-030Jiyeon Jeon

Exposure–response evaluation and simulation studies of IMC-001 using a model incorporating FcRn recycling

Thu, Jun 4, 2026 1:40PM–3:10PM

IV-031John Maringwa

Model Based Meta-Analysis of Disease-Free Survival in Intermediate Risk Non-Muscle Invasive Bladder Cancer (IR-NMIBC) Treated with Mitomycin C or Gemcitabine

Thu, Jun 4, 2026 1:40PM–3:10PM

IV-032Aparna Mohan

QUANTITATIVE SYSTEMS PHARMACOLOGY GUIDED MABEL ESTIMATION FOR T-CELL ENGAGERS (TCE): A CASE STUDY TO SUPPORT MODEL-INFORMED FIRST-IN-HUMAN DOSE SELECTION

Thu, Jun 4, 2026 1:40PM–3:10PM

IV-033Carlos Perez-Ruixo

POPULATION PHARMACOKINETICS AND EXPOSURE-RESPONSE ANALYSIS OF TECLISTAMAB IN COMBINATION WITH DARATUMUMAB IN PARTICIPANTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST ONE PRIOR LINE OF THERAPY.

Thu, Jun 4, 2026 1:40PM–3:10PM

IV-034Daniela Santurio

APPLICATION OF IO SIMULATOR IN IMMUNO-ONCOLOGY COMBINATION THERAPY: A SMALL CELL LUNG CANCER CASE STUDY

Thu, Jun 4, 2026 1:40PM–3:10PM

IV-035Chrisoula Tahtsidou

FROM CAPILLARY TO CLINIC: MODEL-BASED TRANSLATION OF VOLUMETRIC ABSORPTIVE MICROSAMPLING CONCENTRATIONS FOR THERAPEUTIC DRUG MONITORING OF CABOZANTINIB

Thu, Jun 4, 2026 1:40PM–3:10PM

IV-036Debra Van Asten

Population pharmacokinetics of [177Lu]Lu-PSMA-617 combined with EBRT and ADT in treatment naïve patients: differences in tumor uptake and cycle-dependent-effects

Thu, Jun 4, 2026 1:40PM–3:10PM

IV-038Wouter Ahmed

A Joint Model for Torque Teno Virus, Forced Expiratory Volume, Rejection, Infection and Death Dynamics Over a 6-Year Period After Lung Transplantation

Thu, Jun 4, 2026 1:40PM–3:10PM

IV-039Salma Bahnasawy

Population Pharmacokinetic Modelling of AZD1705, a GalNAc-conjugated siRNA targeting ANGPTL3, in Participants with Dyslipidaemia

Thu, Jun 4, 2026 1:40PM–3:10PM

IV-041Jelien Den Hollander

Pharmacokinetic-Pharmacodynamic Modelling of Von Willebrand Factor/Factor VIII Prophylaxis in Von Willebrand Disease

Thu, Jun 4, 2026 1:40PM–3:10PM

IV-042Aanisah Hanuun

A SYNCHRONOUS JOINT POPULATION PHARMACOKINETIC MODEL ANALYSIS FOR THE SIMULTANEOUS ASSESSMENT OF TWO ACTIVE PHARMACEUTICAL INGREDIENTS

Thu, Jun 4, 2026 1:40PM–3:10PM

IV-043Aya Ismail

A PRECLINICAL PK/PD MODEL OF PYRONARIDINE IN SCID MICE: A TRANSLATIONAL WORKFLOW FOR PREDICTING ANTIMALARIAL EFFICACY IN HUMANS

Thu, Jun 4, 2026 1:40PM–3:10PM

IV-044Jasia King

Use of a population pharmacokinetic model to support dose selection for Phase 2a study with AZD4144 IV treatment in participants with acute kidney injury

Thu, Jun 4, 2026 1:40PM–3:10PM

IV-045Pietro Laddomada

Is regrowth of Mycobacterium tuberculosis always a sign of phenotypical resistance? A model-based approach to interpret drug instability and the implications for potency estimation in time-kill assays.

Thu, Jun 4, 2026 1:40PM–3:10PM

IV-046Sophie Marolleau

MECHANISTIC MODELLING OF TARGETED-ANTIBACTERIAL-PLASMIDS TRANSFER VIA BACTERIAL CONJUGATION TO GUIDE DESIGN OF RESISTANCE REVERSAL STRATEGIES

Thu, Jun 4, 2026 1:40PM–3:10PM

IV-047Marina Navas Bachiller

Advancing Antimalarial Therapy Using PBBM: Impact of Physiology and Formulation on Artesunate Absorption

Thu, Jun 4, 2026 1:40PM–3:10PM

IV-048Aglaé Perrin

GENOME WIDE ASSOCIATION STUDY OF MODEL-DERIVED TIME TO VIRAL CLEARANCE IN COVID-19: COMPARISON OF METHODS IN A SIMULATION STUDY AND APPLICATION TO THE DISCOVERY TRIALS.

Thu, Jun 4, 2026 1:40PM–3:10PM

IV-049Abrar Samman

Comparing Cystatin-C with Serum Creatinine for Predicting Vancomycin Clearance in Critically ill pediatric Patients: A Population Pharmacokinetic Study

Thu, Jun 4, 2026 13:40PM–15:10PM

IV-051Anastasia Tsyplakova

Modeling Treatment Response to Secukinumab in Psoriasis Using Machine Learning and Time-to-Event Modeling

Thu, Jun 4, 2026 1:40PM–3:10PM

IV-052Roberto Visentin

Population PK Modelling of Intranasal Midazolam Incorporating Maturation-Informed Paediatric Scaling

Thu, Jun 4, 2026 1:40PM–3:10PM

IV-053Zhigang Wang

Model-based meta-analysis (MBMA) of effect of biologics on FEV1 in severe asthma

Thu, Jun 4, 2026 1:40PM–3:10PM

IV-054Keliang Wu

ETHNIC-SPECIFIC ONTOGENY OF INTESTINAL DRUG TRANSPORTERS AND METABOLIZING ENZYMES IN THE CHINESE POPULATION: ABSOLUTE PROTEOMICS AND TRANSCRIPTOMIC CHARACTERIZATION ACROSS DEVELOPMENT

Thu, Jun 4, 2026 1:40PM–3:10PM

IV-055Darren Crowley

THE EFFECT OF COVARIATES ON TEMOZOLOMIDE EXPOSURE: A POPULATION PHARMACOKINETIC ANALYSIS APPROACH.

Thu, Jun 4, 2026 1:40PM–3:10PM

IV-056Alexandra Lavalley-Morelle

IMPLEMENTING A FULL RANDOM EFFECTS MODEL (FREM) WORKFLOW IN R USING THE SAEMIX PACKAGE

Thu, Jun 4, 2026 1:40PM–3:10PM

IV-057Kamal Srinivasan

Bayesian population PK estimation of linear PK parameters of monoclonal AB with reusable priors for downstream applications.

Thu, Jun 4, 2026 1:40PM–3:10PM

IV-058Amira Ghoneim

Improved Numerical Stability with Phoenix NLME (QRPEM) in a Complex Sequential PK/PD Modeling Workflow

Thu, Jun 4, 2026 1:40PM–3:10PM

IV-059Martin Bergstrand

Reference-Corrected VPCs: Addressing Model Evaluation Challenges with Real-World Data and Adaptive Designs

Thu, Jun 4, 2026 1:40PM–3:10PM

IV-060Zhe Huang

ASSESSMENT OF EXPOSURE-RESPONSE CAUSALITY AND HOMOGENEITY VIA PARTITIONED EFFECTS MODELING AND MEDIATION ANALYSIS: A MOXONIDINE CASE STUDY

Thu, Jun 4, 2026 1:40PM–3:10PM

IV-061Emilie Pilote

RE-ESTIMATION OF PEDIATRIC POPULATION PHARMACOKINETIC MODELS OF DOLUTEGRAVIR IN A CANADIAN POPULATION UNDERGOING THERAPEUTIC DRUG MONITORING

Thu, Jun 4, 2026 1:40PM–3:10PM

IV-062Liam V Brown

A simple algebraic expression can determine if a drug’s clearance is non-specific or target-mediated

Thu, Jun 4, 2026 1:40PM–3:10PM

IV-063Youjung Cho

Characterization and comparison of absorption profiles between three novel sustained-release formulations of oral flucytosine for cryptococcal meningitis treatment through population pharmacokinetic modeling

Thu, Jun 4, 2026 1:40PM–3:10PM

IV-064Charlotte Maria Ursula Dette

PEDIATRIC PBPK MODELING TO SUPPORT THERAPEUTIC DRUG MONITORING OF METHOTREXATE

Thu, Jun 4, 2026 1:40PM–3:10PM

IV-065Silvia Grandoni

Development of a physiologically-based pharmacokinetic model to characterize the drug-drug interaction of the inhaled compound CHF6001 as a victim of CYP3A4 inhibitors

Thu, Jun 4, 2026 1:40PM–3:10PM

IV-066Rebecca Leyla Huber

PHYSIOLOGICALLY BASED PHARMACOKINETIC (PBPK) MODELING OF ANTIDEPRESSANTS: A SCOPING REVIEW OF EXISTING MODELS, APPLICATIONS, AND SOFTWARE TOOLS

Thu, Jun 4, 2026 1:40PM–3:10PM

IV-067Jangik Lee

PHYSIOLOGICALLY BASED PHARMACOKINETIC MODEL FOR PREDICTING FOOD EFFECT ON THE PHARMACOKINETICS OF RADOTINIB

Thu, Jun 4, 2026 1:40PM–3:10PM

IV-068Camille Massaux

Reconstruction of an Advanced Dissolution, Absorption, and Metabolism (ADAM) Model in R: Structural Comparison with Simcyp and PK-Sim

Thu, Jun 4, 2026 1:40PM–3:10PM

IV-069Aleksandr Petrov

Mechanistically informed framework for selection of BBB permeability parameters in PBPK CNS modelling of passively diffusing compounds

Thu, Jun 4, 2026 1:40PM–3:10PM

IV-070SEONGHWA SONG

DEVELOPMENT OF AN INTERSPECIES-SCALED PBPK MODEL AND STRUCTURAL PK–PD FRAMEWORK FOR ABROCITINIB

Thu, Jun 4, 2026 1:40PM–3:10PM

IV-071Daan Van Valkengoed

IN VITRO-IN VIVO EXTRAPOLATION OF ACTIVE INFLUX BY THE PROTON-COUPLED ANTIPORTER FOR PBPK PREDICTIONS OF CNS PHARMACOKINETICS IN EARLY DRUG DISCOVERY: A CASE STUDY ON OXYCODONE

Thu, Jun 4, 2026 1:40PM–3:10PM

IV-072Omar Zaher

Physiologically-based pharmacokinetic modeling to predict human toxicokinetics of the synthetic cannabinoid 5F-Cumyl-P7AICA and its major metabolite: from pig to human translation

Thu, Jun 4, 2026 1:40PM–3:10PM

IV-073Kristin Cecilie Carlsson Petri

POPULATION PHARMACOKINETICS AND EXPOSURE-RESPONSE ANALYSES OF NAVEPEGRITIDE IN CHILDREN WITH ACHONDROPLASIA

Thu, Jun 4, 2026 1:40PM–3:10PM

IV-074Seoyeon Yoon

INTEGRATED POPULATION PHARMACOKINETIC-PHARMACODYNAMIC-EFFICACY ANALYSIS OF ENAVOGLIFLOZIN: LINKING EXPOSURE, GLUCOSURIA, AND HBA1C REDUCTION IN TYPE 2 DIABETES

Thu, Jun 4, 2026 1:40PM–3:10PM

IV-075Laura Boles

Population pharmacokinetics and exposure-response analysis of tideglusib in children and adolescents with congenital myotonic dystrophy type 1

Thu, Jun 4, 2026 1:40PM–3:10PM

IV-076Verena Gotta

CAN AN EXISTING PEDIATRIC PHYSIOLOGICALLY-BASED PREDICTED PHARMACOKINETIC (PBPK) MODEL FOR CEFEPIME BE USED FOR EXTRAPOLATION TO YOUNGER INFANTS?

Thu, Jun 4, 2026 1:40PM–3:10PM

IV-077Anisa Khan

Population pharmacokinetics of aprocitentan and dose rationale for paediatric patients aged from 2 to less than 18 years affected by pulmonary arterial hypertension.

Thu, Jun 4, 2026 1:40PM–3:10PM

IV-078Emily Ratcliffe

QUALIFICATION OF DECISION TABLES FOR SELECTING ACCURATE PAEDIATRIC DRUG CLEARANCE SCALING METHODS

Thu, Jun 4, 2026 1:40PM–3:10PM

IV-079Tarini Singh

USING PKPD MODELLING AND EXTERNAL EVIDENCE TO INFORM PAEDIATRIC EXTRAPOLATION: A CASE STUDY

Thu, Jun 4, 2026 1:40PM–3:10PM

IV-080Aysenur Yaliniz

TOWARD PRECISION DOSING OF CEFTRIAXONE IN CHILDREN WITH SICKLE CELL DISEASE

Thu, Jun 4, 2026 1:40PM–3:10PM

IV-081Nadja Haas

Pharmacometric Evaluation of Patient-Reported Symptom Burden in Oral Anticancer Therapy With Axitinib and Cabozantinib Using Minimal Continuous-time Markov Models

Thu, Jun 4, 2026 1:40PM–3:10PM

IV-082Gabriella Ribeiro

PREDICTION OF DRUG-DRUG INTERACTIONS BETWEEN AYAHUASCA ALKALOIDS AND SSRIS USING PBPK MODELING WITH EXPLORATORY ANALYSIS OF CYP2D6 POLYMORPHISMS AND BREAST MILK EXPOSURE

Thu, Jun 4, 2026 1:40PM–3:10PM

IV-083Yujie Yang

Optimizing Cyclosporine A Therapy in Pregnancy: A Maternal-Fetal Physiologically-Based Pharmacokinetic Modeling Approach

Thu, Jun 4, 2026 13:40PM–15:10PM

IV-084Floris Fauchet

MACHINE LEARNING-BASED COVARIATE SELECTION IN POPULATION PHARMACOKINETICS: A SYSTEMATIC EVALUATION OF BORUTA ALGORITHM WITH TREE-BASED METHODS AGAINST SCM+

Thu, Jun 4, 2026 1:40PM–3:10PM

IV-085Piotr Juszczak

NONMEM IMPLEMENTATION OF NEURAL NETWORKS AS FLEXIBLE MODELS OF HAZARD FUNCTIONS IN JOINT MODELS

Thu, Jun 4, 2026 1:40PM–3:10PM

IV-086HYUNJUNG LEE

Hybrid AI-PBPK Framework for End-to-End Pharmacokinetic Prediction from SMILES

Thu, Jun 4, 2026 1:40PM–3:10PM

IV-087Frano Mihaljevic

mlxModelFinder: Machine Learning–Enhanced Search for Efficient Structural Model Discovery in Monolix

Thu, Jun 4, 2026 1:40PM–3:10PM

IV-088Ana Victoria Ponce-Bobadilla

INTERPRETABLE MACHINE LEARNING-BASED DECISION SUPPORT FOR POPULATION PHARMACOKINETIC DIAGNOSTICS UNDER REALISTIC SHRINKAGE AND SPARSITY CONDITIONS

Thu, Jun 4, 2026 1:40PM–3:10PM

IV-089Jan Rohleff

Next-Generation Pharmacometric Modeling Using Variational Autoencoders

Thu, Jun 4, 2026 1:40PM–3:10PM

IV-090Leonid Stolbov

Simurg ecosystem: a zero-coding agent-driven infrastructure for quantitative pharmacology and MID3 applications

Thu, Jun 4, 2026 1:40PM–3:10PM

IV-091Ilona Blanchard

Model Averaging for Individual Predictions in Joint Nonlinear Mixed-Effects Models

Thu, Jun 4, 2026 1:40PM–3:10PM

IV-092

A NOVEL MATHEMATICAL FRAMEWORK TO PREDICT IN VIVO BISPECIFIC GTX-B001 BINDING IN SKIN AND TRANSLATION TO HUMANS

Thu, Jun 4, 2026 1:40PM–3:10PM

IV-093Anke E. Kip

AN ASYMPTOTIC THEORY ON THE COMPETITIVE BINDING OF THERAPEUTIC AND ENDOGENOUS ANTIBODIES TO FCRN

Thu, Jun 4, 2026 1:40PM–3:10PM

IV-094Nefeli Maria Magaliou

THE TOP-DOWN PBFTPK MODELS VIS A VIS THE BOTTOM-UP PBPK MODELS IN EARLY DRUG DEVELOPMENT

Thu, Jun 4, 2026 13:40PM–15:10PM

IV-095Seongwon Park

QUANTITATIVE MAPPING OF FUNCTIONAL CYTOCHROME P450 ACTIVITIES IN ZEBRAFISH EMBRYOS: INTEGRATING PARENT-METABOLITE DATA VIA TOXICOKINETIC MODELING IN NAMS

Thu, Jun 4, 2026 1:40PM–3:10PM

IV-096Federico Reali

No One-Size-Fits-All: A Multi-Model Evaluation of Optimization-Based and Surrogate-Assisted Virtual Population Generation in QSP

Thu, Jun 4, 2026 1:40PM–3:10PM

IV-097Erik Sjögren

Benchmarking a Mechanistic Immunogenicity Framework: Aligning Sequence-Based Epitope Predictions with Clinical Observations

Thu, Jun 4, 2026 1:40PM–3:10PM

IV-098Stefan Van Den Berg

A Generic IgG Pharmacokinetic Model Applied to Adalimumab and Extended to Capture Anti-Drug Antibody effects

Thu, Jun 4, 2026 1:40PM–3:10PM

IV-099Isabelle ALAKIKI

CROSS-PLATFORM REPRODUCIBILITY OF POPULATION PHARMACOKINETIC MODELING: TRANSLATION FROM NONMEM TO PUMAS

Thu, Jun 4, 2026 1:40PM–3:10PM

IV-100Firas Hammami

BIDIRECTIONAL CONVERSION BETWEEN MRGSOLVE AND RXODE2 FOR PHARMACOMETRIC MODELS

Thu, Jun 4, 2026 1:40PM–3:10PM

IV-101Samer Mouksassi

Real-Time Interactive Visualization in Pharmacometrics: Leveraging Modern Dynamic Graphical Tools for Exploratory Analysis, Diagnostics, and Reporting

Thu, Jun 4, 2026 1:40PM–3:10PM

IV-102Neha Thakre

Bridging insights: Quantitative pharmacology-biostatics collaboration of Population PKPD and Bayesian Logistic Regression Enabling Dosage Selection in Early-Phase Oncology

Thu, Jun 4, 2026 1:40PM–3:10PM

IV-103Annabelle Walz

COMPARISON OF METHODS TO DEMONSTRATE BIOEQUIVALENCE IN CASE OF HIGH VARIABILITY AND GROUP HETEROGENEITY

Thu, Jun 4, 2026 1:40PM–3:10PM

IV-104Chengli Yu

Usage and regulatory acceptance of PBPK models in paediatric drug applications:a review of EMA and FDA public assessment reports

Thu, Jun 4, 2026 1:40PM–3:10PM

IV-105Grace Shalom Govere

CROSS-PRODUCT POPULATION PHARMACOKINETIC MODELING OF HAEMOGLOBIN S POLYMERIZATION INHIBITORS TO OPTIMISE PAEDIATRIC PK STUDY DESIGN USING STOCHASTIC SIMULATION-ESTIMATION

Thu, Jun 4, 2026 1:40PM–3:10PM

IV-106Loes Maton

Advancing sample size justifications in confirmatory paediatric exposure-matching trials submitted to regulatory authorities: a benchmarking analysis and novel methodological framework.

Thu, Jun 4, 2026 1:40PM–3:10PM

IV-107Kevser Sevim

Model‑Informed Strategies for Methocarbamol Multi‑Particulate Regimen Development: Linking Mechanistic Modelling to Formulation Design Space

Thu, Jun 4, 2026 1:40PM–3:10PM

IV-108Axel Vuorinen

PK/PD-INTEGRATED BAYESIAN PLATFORM DESIGN FOR PHASE II REGIMEN OPTIMISATION

Thu, Jun 4, 2026 1:40PM–3:10PM